Qualified participants can earn up to $5,642 in compensation for time and travel. Refer a friend or family to this research study and receive $100.
Precision Clinical Research is enrolling participants for a clinical trial studying two promising medications: Mirikizumab and Tirzepatide, to see how they help people with moderate to severe Crohn’s Disease.
The study lasts about a year, and if you qualify, you could earn up to $5,642. Qualified participants receive:
- Free colonoscopy exams
- DEXA scans
- Nutrition support
- And expert care from a team that’s with you every step of the way
To join, you need to:
- Be 18 to 70 years old
- Have a diagnosed case of Crohn’s
Other criteria and health guidelines apply.
Ages
18 and 70
Study Topics
Study medication
See If You Qualify For This Study
What is Crohn’s Disease?
Crohn’s disease is a health problem that causes swelling and irritation in the digestive system. It can lead to stomach pain, bad diarrhea, feeling tired, losing weight, and not getting enough nutrients.
It can affect different parts of the digestive system for different people. Most often, it shows up at the end of the small intestine and the start of the large intestine. The swelling can go deep into the lining of the gut.
Crohn’s disease can be very painful and hard to live with. Sometimes, it can cause serious health problems.
There is no cure yet, but treatments can help control the symptoms. Some people feel much better and stay that way for a long time with the right care. Many people with Crohn’s can live normal lives.
Key Symptoms of Crohn’s Disease
- Abdominal pain and cramping
- Chronic diarrhea (sometimes bloody)
- Fatigue
- Weight loss
- Fever
- Mouth sores
- Joint pain or skin issues
- Delayed growth in children
This research study is enrolling people who:
Are between ages 18 and 70
Can commit to multiple on-site visits
Do You Not Meet the Criteria for This Study?
You could still participate in other studies. Contact us to be added to our database and you’ll be notified about our future studies that may be right for you.
